Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
Seok Lee, Hyeoung-Joon Kim, June-Won Cheong, Ho-Jin Shin, Jee Hyun Kong, Sang Kyun Sohn, Sung-Soo Yoon, Dae Young Zang, Chul Won Jung, Jeong-A Kim, Sung-Eun Lee, Won Sik Lee, Yunsuk Choi, Inho Kim, Jae Joon Han, Min Kyoung Kim, So Young Chong, Da Jung Kim, Deog-Yeon Jo, Hawk Kim, Jae-Yong Kwak, Je-H · 2026
Read Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia by Seok Lee, Hyeoung-Joon Kim, June-Won Cheong, Ho-Jin Shin, Jee Hyun Kong, Sang Kyun Sohn, Sung-Soo Yoon, Dae Young Zang, Chul Won Jung, Jeong-A Kim, Sung-Eun Lee, Won Sik Lee, Yunsuk Choi, Inho Kim, Jae Joon Han, Min Kyoung Kim, So Young Chong, Da Jung Kim, Deog-Yeon Jo, Hawk Kim, Jae-Yong Kwak, Je-H (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13331954.txt.
Description
Seok Lee and colleagues report 2026 real-world results for ponatinib in Korean patients whose blood cancers had already resisted earlier drugs. The study followed 148 people across 24 sites: most had chronic myeloid leukemia in chronic, accelerated, or blast phase, and 33 had Philadelphia chromosome-positive acute lymphoblastic leukemia. Many had failed prior kinase-blocking drugs or carried the T315I mutation. Most started at 45 milligrams once daily, often as third-line therapy.
In chronic-phase leukemia, about four in ten patients reached a major molecular response, and earlier use gave stronger deep responses than later use. Response rates were higher still in the lymphoblastic leukemia group. Rash, high blood pressure, and fever were the most common side effects, and two vascular blockage events occurred. The authors judge the drug usefully effective with manageable safety in this hard-to-treat group, with early high-dose use looking most promising.
Catalog record
| CREATOR | Seok Lee, Hyeoung-Joon Kim, June-Won Cheong, Ho-Jin Shin, Jee Hyun Kong, Sang Kyun Sohn, Sung-Soo Yoon, Dae Young Zang, Chul Won Jung, Jeong-A Kim, Sung-Eun Lee, Won Sik Lee, Yunsuk Choi, Inho Kim, Jae Joon Han, Min Kyoung Kim, So Young Chong, Da Jung Kim, Deog-Yeon Jo, Hawk Kim, Jae-Yong Kwak, Je-H |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |